The safety profile of moxifloxacin and other fluoroquinolones in special patient populations

References

• Lode H, Allewelt M. Role of newer fluoroquinolones in lower respiratory tract infections. J Antimicrob Chemother 2002;49:709–12
   PubMed Web of Science ®Google Scholar
• Wise R, Honeybourne D. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Eur Respir J 1999;14:221–9
   PubMed Web of Science ®Google Scholar
• Stein GE, Goldstein EJC. Fluoroquinolones and anaerobes. Clin Infect Dis 2006;42:1598–607
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 2002;62:13–59
   PubMed Web of Science ®Google Scholar
• Gellert M, Mizuuchi K, O’Dea MH, Nash HA. DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc Natl Acad Sci USA 1976;73:3872–6
   PubMed Web of Science ®Google Scholar
• Muller M, Stass H, Brunner M, et al. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother 1999;43:2345–9
   PubMed Web of Science ®Google Scholar
• Wirtz M, Kleeff J, Swoboda S, et al. Moxifloxacin penetration into human gastrointestinal tissues. J Antimicrob Chemother 2004;53:875–7
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of communityacquired pneumonia in adults. Clin Infect Dis 2007;44 (Suppl 2):S27–S72
   PubMedGoogle Scholar
• Lode H, Rubinstein E. Adverse effects. In: Hooper DC, Rubinstein E, editors. Quinolone antimicrobial agents, 3rd ed. Washington (DC): ASM Press; 2003. p. 407–19
   Google Scholar
• Stahlmann R. Clinical toxicological aspects of fluoroquinolones. Toxicol Lett 2002;127:269–77
   PubMed Web of Science ®Google Scholar
• Stahlmann R, Lode H. Fluoroquinolones in the elderly: safety considerations. Drugs Aging 2003;20:289–02
   PubMed Web of Science ®Google Scholar
• Kasama R, Sorbello A. Renal and electrolyte complications associated with antibiotic therapy. Am Fam Physician 1996;53:227–32
   PubMed Web of Science ®Google Scholar
• Owens Jr RC, Ambrose PG. Clinical use of the fluoroquinolones. Med Clin North Am 2000;84:1447–69
   PubMed Web of Science ®Google Scholar
• Islinger F, Bouw R, Stahl M, et al. Concentrations of gemifloxacin at the target site in healthy volunteers after a single oral dose. Antimicrob Agents Chemother 2004;48: 4246–9
   PubMed Web of Science ®Google Scholar
• Gee T, Andrews JM, Ashby JP, et al. Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose. J Antimicrob Chemother 2001;47:431–4
   PubMed Web of Science ®Google Scholar
• Noreddin AM, Hoban DJ, Zhanel GG. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalized patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. Int J Antimicrob Agents 2005;26: 120–5
   Google Scholar
• Andriole VT, Haverstock DC, Choudhri SH. Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Drug Saf 2005;28: 443–52
   Google Scholar
• Ball P, File TM, Twynholm M, et al. Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. Int J Antimicrob Agents 2001;18:19–27
   PubMed Web of Science ®Google Scholar
• Anzueto A, Niederman MS, Pearle J, et al. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006;42:73–81
   PubMed Web of Science ®Google Scholar
• Shorr AF, Zadeikis N, Xiang JX, et al. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or = 65 years with community-acquired pneumonia. Clin Ther 2005;27:1251–9
   PubMed Web of Science ®Google Scholar
• Westphal JF, Vetter D, Brogard JM. Hepatic side-effects of antibiotics. J Antimicrob Chemother 1994;33:387–401
   PubMed Web of Science ®Google Scholar
• Anon. Levaquin (levofloxacin) [package insert]. Raritan (NJ): Ortho-McNeil Pharmaceutical Inc.; 2006
   Google Scholar
• Anon. Tequin (gatifloxacin) [package insert]. Princeton (NJ): Bristol-Myers Squibb Company; 2006
   Google Scholar
• Anon. Avelox (moxifloxacin) [package insert]. Kenilworth (NJ): Bayer Pharmaceuticals Corporation; 2005
   Google Scholar
• Anon. Factive (gemifloxacin) [package insert]. Waltham (MA): Oscient Pharmaceuticals; 2006
   Google Scholar
• Nicholson SC, Webb CD, Moellering Jr RC. Antimicrobial-associated acute hepatitis. Pharmacotherapy 2002;22:794–6
   Google Scholar
• Henann NE, Zambie MF. Gatifloxacin-associated acute hepatitis. Pharmacotherapy 2001;21:1579–82
   PubMed Web of Science ®Google Scholar
• Karim A, Ahmed S, Rossoff LJ, et al. Possible levofloxacin-induced acute hepatocellular injury in a patient with chronic obstructive lung disease. Clin Infect Dis 2001;33:2088–90
   PubMed Web of Science ®Google Scholar
• Airey K, Koller E. Acute hepatitis associated with levofloxacin in a patient with renal insufficiency. Can Mede Assoc J 2003;169:755
   Web of Science ®Google Scholar
• Nori S, Nebesio C, Brashear R, Travers JB. Moxifloxacin-associated drug hypersensitivity syndrome with toxic epidermal necrolysis and fulminant hepatic failure. Arch Dermatol 2004;140:1537–8
   PubMed Web of Science ®Google Scholar
• Zaidi SA. Hepatitis associated with amoxicillin/clavulanic acid and/or ciprofloxacin. Am J Med Sci 2003;325:31–3
   PubMed Web of Science ®Google Scholar
• Lata J, Jurankova J, Husova L, et al. Variceal bleeding in portal hypertension: bacterial infection and comparison of efficacy of intravenous and per-oral application of antibiotics – a randomized trial. Eur J Gastroenterol Hepatol 2005;17: 1105–10
   PubMed Web of Science ®Google Scholar
• Anon. Cipro (ciprofloxacin) [package insert]. Kenilworth (NJ): Bayer Pharmaceuticals Corporation; 2005
   Google Scholar
• Lomaestro BM. Fluoroquinolone-induced renal failure. Drug Saf 2000;22:479–85
   PubMed Web of Science ®Google Scholar
• Famularo G, De SC. Nephrotoxicity and purpura associated with levofloxacin. Ann Pharmacother 2002;36:1380–2
   PubMed Web of Science ®Google Scholar
• Ramalakshmi S, Bastacky S, Johnson JP. Levofloxacin-induced granulomatous interstitial nephritis. Am J Kidney Dis 2003; 41:E7
   Google Scholar
• Sowinski KM, Lucksiri A, Kays MB, et al. Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer. Am J Kidney Dis 2003;42:342–9
   PubMed Web of Science ®Google Scholar
• Bellmann R, Egger P, Gritsch W, et al. Elimination of levofloxacin in critically ill patients with renal failure: influence of continuous veno-venous hemofiltration. Int J Clin Pharmacol Ther 2002;40:142–9
   PubMed Web of Science ®Google Scholar
• Guenter SG, Iven H, Boos C, et al. Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients. Pharmacotherapy 2002;22:175–83
   PubMed Web of Science ®Google Scholar
• Bellmann R, Egger P, Gritsch W, et al. Pharmacokinetics of ciprofloxacin in patients with acute renal failure undergoing continuous venovenous haemofiltration: influence of concomitant liver cirrhosis. Acta Med Austriaca 2002;29:112–6
   PubMedGoogle Scholar
• Stass H, Kubitza D, Halabi A, et al. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br J Clin Pharmacol 2002;53:232–7
   PubMed Web of Science ®Google Scholar
• Fuhrmann V, Schenk P, Jaeger W, et al. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. J Antimicrob Chemother 2004;54: 780–4
   PubMed Web of Science ®Google Scholar
• Saraya A, Yokokura M, Gonoi T, Seino S. Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels. Eur J Pharmacol 2004;497:111–7
   PubMed Web of Science ®Google Scholar
• Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. New Engl J Med 2006;354:1352–61
   PubMed Web of Science ®Google Scholar
• Blommel AL, Lutes RA. Severe hyperglycemia during renally adjusted gatifloxacin therapy. Ann Pharmacother 2005;39: 1349–52
   PubMed Web of Science ®Google Scholar
• Arce FC, Bhasin RS, Pasmantier R. Severe hyperglycemia during gatifloxacin therapy in patients without diabetes. Endocr Pract 2004;10:40–4
   Google Scholar
• Tailor SA, Simor AE, Cornish W, et al. Glucose homeostasis abnormalities and gatifloxacin. Clin Infect Dis 2006;42:895
   PubMed Web of Science ®Google Scholar
• Mohr JF, McKinnon PS, Peymann PJ, et al. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy 2005;25:1303–9
   PubMed Web of Science ®Google Scholar
• Friedrich LV, Dougherty R. Fatal hypoglycemia associated with levofloxacin. Pharmacotherapy 2004;24:1807–12
   PubMed Web of Science ®Google Scholar
• Graumlich JF, Habis S, Avelino RR, et al. Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study. Pharmacotherapy 2005;25:1296–302
   PubMed Web of Science ®Google Scholar
• Gavin III JR, Kubin R, Choudhri S, et al. Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies. Drug Saf 2004;27:671–86
   PubMed Web of Science ®Google Scholar
• Portier H, Brambilla C, Garre M, et al. Moxifloxacin mono-therapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors. Eur J Clin Microbiol Infect Dis 2005;24: 367–76
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. New drug applications. Rates of hypoglycemia. Available at: http://www.fda.gov/cder/ approval/index.htm [accessed 09 March 2007]
   Google Scholar
• Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003;89:1363–72
   PubMed Web of Science ®Google Scholar
• Iannini PB. Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval. Expert Opin Drug Saf 2002;1:121–8
   PubMedGoogle Scholar
• Sanguinetti MC, Jurkiewicz NK. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990;96:195–215
   Google Scholar
• De PF, Poluzzi E, Cavalli A, et al. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf 2002;25:263–86
   PubMed Web of Science ®Google Scholar
• Owens Jr RC. QT prolongation with antimicrobial agents: understanding the significance. Drugs 2004;64:1091–124
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Camm J. Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother 2002;49:593–6
   PubMed Web of Science ®Google Scholar
• Katritsis D, Camm AJ. Quinolones: cardioprotective or cardiotoxic. Pacing Clin Electrophysiol 2003;26:2317–20
   PubMed Web of Science ®Google Scholar
• Cubeddu LX. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther 2003;10:452–7
   PubMedGoogle Scholar
• Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. J Am Med Assoc 2003;289:2120–7
   Google Scholar
• Owens Jr RC, Ambrose PG. Torsades de pointes associated with fluoroquinolones. Pharmacotherapy 2002;22:663–8
   PubMed Web of Science ®Google Scholar
• Curtis LH, Ostbye T, Sendersky V, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 2003;114:135–41
   PubMed Web of Science ®Google Scholar
• Noel GJ, Natarajan J, Chien S, et al. Effects of three fluoro-quinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 2003;73:292–03
   PubMed Web of Science ®Google Scholar
• Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001;21:1468–72
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents 2007;29:374–9
   PubMedGoogle Scholar
• Morganroth J, Dimarco JP, Anzueto A, et al. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 2005;128:3398–406
   PubMed Web of Science ®Google Scholar